多瑞医药(301075.SZ)拟设立西藏瑞升祥医药有限公司

Core Viewpoint - Duori Pharmaceutical (301075.SZ) has announced the establishment of a wholly-owned subsidiary, Tibet Ruishengxiang Pharmaceutical Co., Ltd., with a registered capital of 2 million yuan to optimize its headquarters management functions based on operational and strategic development needs [1]. Group 1 - The company is focusing on enhancing its management capabilities through the formation of a new subsidiary [1]. - The registered capital for the new subsidiary is set at 2 million yuan [1].